Cybrexa Therapeutics

Executive Summary

Cybrexa Therapeutics is a private, oncology-focused platform company developing antigen-independent tumor targeting with deep tissue penetration for small molecule anti-cancer drugs. Founded in 2017 by physician-scientists and an experienced management team, the company aims to overcome key limitations of conventional cancer therapies, such as lack of targeting specificity and poor tumor penetration. Its proprietary technology enables small molecule drugs to selectively accumulate in tumors and metastases regardless of antigen expression, potentially broadening the therapeutic window and improving patient outcomes. Cybrexa's lead program is in Phase 2 clinical development, targeting solid tumors. The platform's versatility suggests potential for multiple indications and combination therapies. With a strong scientific foundation and experienced leadership, Cybrexa is positioned to address significant unmet needs in oncology, though it remains at an early clinical stage with inherent development risks. The company's progress toward proof-of-concept data will be critical for near-term value inflection.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 interim efficacy data readout for lead candidate50% success
• Q4 2026Announcement of strategic licensing or partnership deal40% success
• Q2 2027Preclinical IND filing for next-generation pipeline asset70% success